Design and Processing of Nanogels As Delivery Systems for Peptides and Proteins

Arnfast, Lærke; Madsen, Claus; Jørgensen, Lene; Baldursdóttir, Stefanía

doi:10.4155/tde.14.38

Cited by 31 publications

(21 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include high hydrophilicity, high loading capacity for drugs, high biocompatiblity, softness, and swelling. But the main advantage of nanogels is their fast response to environmental changes, which can help control their response at the target site (Arnfast, Madsen, Jorgensen, & Baldursdottir, 2014;Hamzah, Hashim, & Rahman, 2017;Soni, Desale, & Bronich, 2016). Despite these benefits, high cost requiring to remove the solvents and surfactants at the end of preparation, and toxicity resulting from remained surfactant or monomer traces are drawbacks (Zarekar, Lingayat, & Pande, 2017).…”

Section: Encapsulated 17-aag In Nanogelsmentioning

confidence: 99%

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

et al. 2019

View full text Add to dashboard Cite

Hsp90 is a ubiquitous chaperone with important roles in the organization and maturation of client proteins that are involved in the progression and survival of cancer cells. Multiple oncogenic pathways can be affected by inhibition of Hsp90 function through degradation of its client proteins. That makes Hsp90 a therapeutic target for cancer treatment. 17‐allylamino‐17‐demethoxy‐geldanamycin (17‐AAG) is a potent Hsp90 inhibitor that binds to Hsp90 and inhibits its chaperoning function, which results in the degradation of Hsp90's client proteins. There have been several preclinical studies of 17‐AAG as a single agent or in combination with other anticancer agents for a wide range of human cancers. Data from various phases of clinical trials show that 17‐AAG can be given safely at biologically active dosages with mild toxicity. Even though 17‐AAG has suitable pharmacological potency, its low water solubility and high hepatotoxicity could significantly restrict its clinical use. Nanomaterials‐based drug delivery carriers may overcome these drawbacks. In this paper, we review preclinical and clinical research on 17‐AAG as a single agent and in combination with other anticancer agents. In addition, we highlight the potential of using nanocarriers and nanocombination therapy to improve therapeutic effects of 17‐AAG.

show abstract

Section: Encapsulated 17-aag In Nanogelsmentioning

confidence: 99%

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Four different classes of polymers have been hitherto exploited for the preparation of nanogels. These include polyacrylates, poloxamer or polyethylene glycol, polypeptides and polysaccharides [ 108 ]. One of the most widely investigated nanogel systems for sustained drug delivery are self-assembled hydrophobized polysaccharides, such as cholesterol-bearing pullulan (CHP) [ 109 ].…”

Section: Modification Of the Drug Releasementioning

confidence: 99%

Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art

2020

View full text Add to dashboard Cite

Within recent decades, the development of nanotechnology has made a significant contribution to the progress of various fields of study, including the domains of medical and pharmaceutical sciences. A substantially transformed arena within the context of the latter is the development and production of various injectable parenteral formulations. Indeed, recent decades have witnessed a rapid growth of the marketed and pipeline nanotechnology-based injectable products, which is a testimony to the remarkability of the aforementioned contribution. Adjunct to the ability of nanomaterials to deliver the incorporated payloads to many different targets of interest, nanotechnology has substantially assisted to the development of many further facets of the art. Such contributions include the enhancement of the drug solubility, development of long-acting locally and systemically injectable formulations, tuning the onset of the drug’s release through the endowment of sensitivity to various internal or external stimuli, as well as adjuvancy and immune activation, which is a desirable component for injectable vaccines and immunotherapeutic formulations. The current work seeks to provide a comprehensive review of all the abovementioned contributions, along with the most recent advances made within each domain. Furthermore, recent developments within the domains of passive and active targeting will be briefly debated.

show abstract

“…Hence, we exploited a kind of non-degradable nanogel as substrates of enzymes are often small molecules. The protection ability of nanogels was mainly dependent on the polymeric shells formed by monomers [42,43]. Therefore, through changing the crosslinkers, we could also design the responsive-release nanogels with high protection ability to load other functional protein drugs, such as monoclonal antibodies [44] and growth factors [4], on scaffolds with organic coatings.…”

Section: The Detection Of the Ros Concentration In 4t1 Cellsmentioning

confidence: 99%

The Stability Maintenance of Protein Drugs in Organic Coatings Based on Nanogels

Yang

Shan

et al. 2020

Pharmaceutics

View full text Add to dashboard Cite

Protein drugs are often loaded on scaffolds with organic coatings to realize a spatiotemporal controlled release. The stability or activity of protein drugs, however, is largely affected by the organic coating, particularly with organic solvents, which can dramatically reduce their delivery efficiency and limit their application scope. In spite of this, little attention has been paid to maintaining the stability of protein drugs in organic coatings, to date. Here, we used catalase as a model protein drug to exploit a kind of chemically cross-linked nanogel that can efficiently encapsulate protein drugs. The polymeric shells of nanogels can maintain the surface hydration shell to endow them with a protein protection ability against organic solvents. Furthermore, the protection efficiency of nanogels is higher when the polymeric shell is more hydrophilic. In addition, nanogels can be dispersed in polylactic acid (PLA) solution and subsequently coated on scaffolds to load catalase with high activity. To the best of our knowledge, this is the first use of hydrophilic nanogels as a protection niche to load protein drugs on scaffolds through an organic coating, potentially inspiring researchers to exploit new methods for protein drug loading.

show abstract

Design and Processing of Nanogels As Delivery Systems for Peptides and Proteins

Cited by 31 publications

References 116 publications

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art

The Stability Maintenance of Protein Drugs in Organic Coatings Based on Nanogels

Contact Info

Product

Resources

About